NanoEcho’s core values
Through responsibility, commitment, focus, and reliable delivery, we create value.
These core values not only represent our principles but also our commitment and endeavor to live up to them in every task we undertake. Our goal is to let these values guide us in all our tasks.
Responsibility: We take responsibility for our commitments and tackle challenges with determination. We take ownership and deliver as promised. We speak truthfully and, when uncertain, offer clarity by presenting facts. Through openness, we build trust.
Commitment: With a burning passion for our customers and our mission, we have strong faith in our solution, our product, and our capabilities. We engage collaboratively with customers, colleagues, owners, suppliers, and stakeholders. Together, we strive to meet high expectations.
Focus: With courage and determination, we steer towards our goal. By daring to prioritize, we create value for our customers. We remain focused on fulfilling our customers’ needs.
Delivery: We work to create value, to deliver to our customers, and to keep our promises. Through knowledge, innovation, and collaboration, we ensure quality-driven deliveries.
Management and board
The management consists of people with solid experience and knowledge in medical technology and commercialization. There is also a background of successfully driving products from idea stage to successful launches
Board of directors
CEO
Number of shares in NanoEcho: 50.000
E-mail: lp@nanoecho.se
Linda Persson has a PhD in medical technology and has extensive experience from several leading positions with focus on product development. She comes most recently from a senior role in the strategy and business development department at E.ON. Before that, Linda also held influential positions at other companies, such as Baxter and Sony
CTO
Number of shares in NanoEcho: 66.000
E-mail: ms@nanoecho.se
Magnus Santesson is educated at Lund University in computer science. Magnus has solid experience as a program and project manager for technical global development projects in fast-moving consumer goods and medical technology. He co-founded and developed Mobytech Consulting, which had 28 employees before it was sold to a French consulting company.
Henrik Ljung
CFO
Number of shares in NanoEcho: 21.953 (via Ljung & Winbladh AB)
E-mail: hl@nanoecho.se
Henrik Ljung has an MBA and has several years of experience as the CFO of Cerdo Bankpartner AB, Acconeer AB, Ballingslöv AB, Sardus AB, and Malmöhus Invest AB, among others.
Dr. Ulrika Axelsson
Clinical Director
Number of shares in NanoEcho: 0
E-mail: ua@nanoecho.se
Ulrika Axelsson has a Ph.D. in Immunotechnology and has experience in running clinical trials. Most recently she had a position as business coach at SmiLe Life Science Incubator. Before that, Ulrika worked at PainDrainer AB and in leading positions at CREATE Health Translational Cancer Center, with the aim of commercializing research in oncology.
CEO
Linda Persson has a PhD in medical technology and has extensive experience from several leading positions with focus on product development. She comes most recently from a senior role in the strategy and business development department at E.ON. Before that, Linda also held influential positions at other companies, such as Baxter and Sony
CTO
Magnus Santesson is educated at Lund University in computer science. Magnus has solid experience as a program and project manager for technical global development projects in fast-moving consumer goods and medical technology. He co-founded and developed Mobytech Consulting, which had 28 employees before it was sold to a French consulting company.
Henrik Ljung
CFO
Antal aktier: 21.953 (via Ljung & Winbladh AB)
Henrik Ljung has an MBA and has several years of experience as the CFO of Cerdo Bankpartner AB, Acconeer AB, Ballingslöv AB, Sardus AB, and Malmöhus Invest AB, among others.
Dr. Ulrika Axelsson
Clinical Director
Ulrika Axelsson has a Ph.D. in Immunotechnology and has experience in running clinical trials. Most recently she had a position as business coach at SmiLe Life Science Incubator. Before that, Ulrika worked at PainDrainer AB and in leading positions at CREATE Health Translational Cancer Center, with the aim of commercializing research in oncology.
Board
Daniel Johnsson
Chairman of the board
Number of shares in NanoEcho: 5.933.355 (via Quiq Holding AB)
University studies at Chalmers University of Technology and the Gothenburg School of Business. 25 years of experience as CEO of Exertis Nordics AB, of which the last 7 years in a listed group. He has a history of being a serial entrepreneur with several successful exits. Today active as investor and adviser.
Chairman of the Board in: Postery AB, Renable AB, Admazing AB och Brink Commerce AB. Board member in: IRLAB Therapeutics AB, Integrative Research Laboratories Sweden AB, Quiq Holding AB, CapTech Holding AB, JOSI Holding AB, JHD Holding AB, Tura Group AB, Flower Infrastructure Technologies AB, Chilimobil Sweden AB, DB24 AB och Hilke Collection AB.
Dr. Ann-Christin Malmborg Hager
Member of the board
Number of shares in NanoEcho: 0
Has long experience in starting companies in life science. Previous experience includes CEO of PainDrainer AB, SenzaGen AB, DiaProst AB, Cantargia AB and XImmune AB. She has worked as Investment Director at LU Bioscience and VP Business Development at Alligator Bioscience AB. Today she works as CEO at Uptake Bio AB, advisory to start-up companies, and Board Member of SenzaGen AB, Lead Biologics International AB, Avena Partners AB, and Hager Consulting AB.
Åke Bengtsson
Member of the board
Number of shares in NanoEcho: 0
Åke has a long experience in executive roles as CFO and CEO at various manufacturing industries with an international footprint. Åke holds an Executive MBA from SIMI Copenhagen. He currently run his own business offering interim services in business advisory and management. Åke is a Business Coach at Produktionsänglar, Södertälje Science Park, and Senior Business Advisor at SMILE Incubator. Åke is a board member of Nosterix AB.
Dr. Tord Labuda
Member of the board
Number of shares in NanoEcho: 0
Tord has a Ph.D. in Tumor Immunology from Lund University and has more than 15 years of international experience from leading positions in the pharmaceutical industry, primarily in R&D but also in commercial roles. Today, Tord is operational as Vice President and Global Head of Clinical Development at LEO Pharma in Denmark. Tord’s passion lies in leadership, strategic guidance to new patient solutions, and creating commercial value.
Daniel Johnsson
Chairman of the board
Number of shares in NanoEcho: 5.933.355 (via Quiq Holding AB)
University studies at Chalmers University of Technology and the Gothenburg School of Business. 25 years of experience as CEO of Exertis Nordics AB, of which the last 7 years in a listed group. He has a history of being a serial entrepreneur with several successful exits. Today active as investor and adviser.
Chairman of the Board in: Oblique Therapeutics AB (publ), Postery AB, Renable AB, Admazing AB. Board member in: Quiq Holding AB, Flower Infrastructure Technologies AB, Playground TV AB, Chillimobil AB, Workpilots Oy.
Dependent in relation to the major shareholders and independent in relation to the Company.
Dr. Ann-Christin Malmborg Hager
Member of the board
Number of shares in NanoEcho: 0
Has long experience in starting companies in life science. Previous experience includes CEO of PainDrainer AB, SenzaGen AB, DiaProst AB, Cantargia AB and XImmune AB. She has worked as Investment Director at LU Bioscience and VP Business Development at Alligator Bioscience AB. Today she works as CEO at Uptake Bio AB, advisory to start-up companies, and Board Member of SenzaGen AB, Lead Biologics International AB, Avena Partners AB, and Hager Consulting AB.
Independent in relation to the Company and to major shareholders.
Åke Bengtsson
Member of the board
Number of shares in NanoEcho: 0
Åke has a long experience in executive roles as CFO and CEO at various manufacturing industries with an international footprint. Åke holds an Executive MBA from SIMI Copenhagen. He currently run his own business offering interim services in business advisory and management. Åke is a Business Coach at Produktionsänglar, Södertälje Science Park, and Senior Business Advisor at SMILE Incubator. Åke is a board member of Nosterix AB.
Independent in relation to the Company and to major shareholders.
Dr. Tord Labuda
Member of the board
Number of shares in NanoEcho: 0
Tord has a Ph.D. in Tumor Immunology from Lund University and has more than 15 years of international experience from leading positions in the pharmaceutical industry, primarily in R&D but also in commercial roles. Today, Tord is operational as Vice President and Global Head of Clinical Development at LEO Pharma in Denmark. Tord’s passion lies in leadership, strategic guidance to new patient solutions, and creating commercial value.
Independent in relation to the Company and to major shareholders.
Dependent in relation to the major shareholders and independent in relation to the Company.
Independent in relation to the Company and to major shareholders.
Independent in relation to the Company and to major shareholders.
Independent in relation to the Company and to major shareholders.
